Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Participants diagnosed with moderately to severely active ulcerative colitis (UC) defined by a Mayo score of 6 to 12 inclusive at Baseline (Week 0), including an endoscopic (examination of an internal part of the body with a lighted tube; looking at a part of the body with a lighted tube) subscore of greater than or equal to 2~* Participants must have biopsy results (collected at the screening endoscopy (procedure or obtained within the last year) consistent with the diagnosis of UC~* Participants either currently receiving treatment with, or have a history of failure to respond to, or tolerate, at least 1 of the following therapies: oral 5-aminosalicylate (5-ASAs), oral corticosteroids, 6-mercaptopurine (6-MP) and azathioprine (AZA)~* Participants with current dependency or with a history of corticosteroid dependency (i.e. an inability to successfully taper corticosteroids without a return of the symptoms of UC) - Not have a diagnosis of active TB~Exclusion Criteria:~* Participants with previous exposure to biologic anti-tumor necrosis factor (TNF) agents~* Participants with severe extensive UC that is likely to require a colectomy (surgery to remove part or all of the colon) within 12 weeks of study entry~* Participants having UC limited to the rectum only or to less than 20 centimeter (cm) of the colon~* Presence of a stoma (an artificial permanent opening especially in the abdominal wall made in surgical procedures) or presence of a fistula~* Participants with a history of extensive colonic resection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo for golimumab, intravenous (IV) (through a vein in the arm) infusion administered at Week 0
- Golimumab 1 milligram (mg) per kilogram (kg) (Type: EXPERIMENTAL): Golimumab 1 mg per kg intravenous (IV) infusion administered at Week 0.
- Golimumab 2 mg per kg (Type: EXPERIMENTAL): Golimumab 2 mg per kg intravenous (IV) infusion administered at Week 0.
- Golimumab 4 mg per kg (Type: EXPERIMENTAL): Golimumab 4 mg per kg, intravenous (IV) infusion administered at Week 0.

Based on this trial design, predict the completion outcome and termination type (if applicable).